Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 2, 2010, Pages 156-161

  Kawamura, Masaki ^a   Konishi, Noriko ^b   Hiroe, Katsuhiko ^b   Shofuda, Ken Ichi ^b   Imaeda, Yasuhiro ^b   Fujimoto, Takuya ^b   Kubo, Keiji ^b  

^a TAKEDA PHARMACEUTICALS   (United States)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [ 3 [(6 CHLORONAPHTHALEN 2 YL)SULFONYL] 2 HYDROXYPROPANOYL]PIPERIDIN 4 YL]TETRAHYDROPYRIMIDIN 2(1H) ONE; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MELAGATRAN; RIVAROXABAN; TAK 442; THROMBIN; UNCLASSIFIED DRUG; XIMELAGATRAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SELECTIVITY; MALE; MONKEY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; THROMBOGENESIS; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BLEEDING TIME; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOGS; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED ICR; MORPHOLINES; PYRAZOLES; PYRIDONES; PYRIMIDINONES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; THIOPHENES; THROMBIN; VENOUS THROMBOSIS;

EID: 77955984416     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181e2bfcf     Document Type: Article

References (16)

1. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:S160-S198.
2. Mousa SA, Abdel-Razeq HN. Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge? Cardiovasc Drug Rev. 2005;23:331-344.
3. Baetz BE, Spinler SA. Dabigatran Etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy. 2008;28:1354-1373.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al; the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
5. Garcia D, Libby E, Crowther M.A. The new oral anticoagulants. Blood. 2010;115:15-20.
6. Duggan ST, Scott LJ, Plosker GL. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs. 2009;69:1829-1851.
7. Bieth GB. Theoretical and practical aspects of proteinase inhibition kinetics. Methods Enzymol. 1995;248:59-84.
8. Smith SA, Morrissey JH. Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct factor Xa inhibitors (ASH Annual Meeting Abstracts). Blood. 2007;110:928.
9. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther. 2007;45:335-344.
10. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor, in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47:203-216.
11. Stringer F, Scott G, Kupfer S, et al. The pharmacokinetics and pharmacodynamics of TAK-442, an oral, direct factor Xa inhibitor following multiple dosing in healthy male subjects [British Pharmacological Society web site]. 2009. Available at: https://bps.conference-services.net/resources/ 344/1934/pdf/WINTER09-0062.pdf. Accessed December 20, 2009.
12. Weitz JI, Cao C, Eriksson B, et al. Phase II dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective knee arthroplasty (ASH Annual Meeting Abstracts). Blood. 2009;114:170.
13. Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008;143:180-190.
14. Aznar J, Vaya A, Estelles A, et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V leiden and their interaction with oral contraceptives. Haematologica. 2000;85:1271-1276.
15. Morishima Y, Tanabe K, Terada Y, et al. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost. 1997;78:1366-1371.
16. Wong PC, Crain EJ, Watson CA, et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost. 2009;7:1313-1320.